Rat Vascular Endothelial Growth Factor A (VEGFA) Protein (Active)

Catalogue No.:abx651461



Western blot analysis of recombinant Rat VEGFA, using VEGFA antibody.



SDS-PAGE analysis of recombinant Rat VEGFA.



Gene sequencing extract of Rat VEGFA.



Cell proliferation analysis of ECV304 cells cultured in serum-free DMEM after stimulation with 10 ng/ml VEGFA for 72 h.

Cell proliferation analysis of unstimulated ECV304 cells cultured in serum-free DMEM for 72 h.

Abbexa LTD, Cambridge, UK · Phone: +44 (0) 1223 755950 · Fax: +44 (0) 1223 755951
Abbexa LLC, Houston, TX USA · Phone: +1 832 327 7413
Abbexa BV, Leiden, NL
Website: www.abbexa.com · Email: info@abbexa.com



Dose-effect analysis of VEGFA on ECV304 cells.

Vascular Endothelial Growth Factor A (VEGFA) Protein (Active) is an active protein from Rat.

Target:	Vascular Endothelial Growth Factor A (VEGFA)
Origin:	Rat
Tested Applications:	WB, SDS-PAGE
Host:	293F cell
Conjugation:	Unconjugated
Form:	Lyophilized
Purity:	> 98%
Reconstitution:	To keep the original salt concentration, we recommend reconstituting to the original concentration prior to lyophilization (see Concentration) in ddH_2O. If a lower concentration is required, dilute in PBS, pH 7.4. If a higher concentration is required, the product can be reconstituted directly in PBS, pH 7.4, though please note that this will change the overall salt concentration. The stock concentration should be between 0.1-1.0 mg/ml. Do not vortex.
Storage:	Store at 2-8 °C for up to one month. Store at -80 °C for up to one year. Avoid repeated freeze/thaw cycles.
UniProt Primary AC:	P16612 (UniProt, ExPASy)
Molecular Weight:	Calculated MW: 20.8 kDa Observed MW: 22 kDa
Sequence Fragment:	Ala27-Arg190
Tag:	N-terminal His tag
Buffer:	Prior to lyophilization: PBS, pH 7.4, containing 0.01% Sarcosyl, 1 mM DTT, 5% Trehalose and Proclin-300.

Abbexa LTD, Cambridge, UK · Phone: +44 (0) 1223 755950 · Fax: +44 (0) 1223 755951
Abbexa LLC, Houston, TX USA · Phone: +1 832 327 7413
Abbexa BV, Leiden, NL
Website: www.abbexa.com · Email: info@abbexa.com

Activity: Active

Biological Activity: VEGFA is known to induce vascular permeability and growth, promote monocyte/macrophage migration, and inhibit cell apoptosis. To test the effect of VEGFA on cell proliferation of the ECV304 endothelium cell line, cells were seeded into triplicate wells of 96-well plates at a density of 2,000 cells/well and allowed to attach overnight, then the medium was replaced with serum-free standard DMEM prior to the addition of various concentrations of VEGFA. After incubation for 72 h, cells were observed using an inverted microscope and cell proliferation was measured by Cell Counting Kit-8 (CCK-8). Briefly, 10 µl of CCK-8 solution was added to each well of the plate, which was incubated for 1-4 hours at 37°C. The absorbance was then measured at 450 nm using a microplate reader. Cell proliferation of ECV304 cells after incubation with VEGFA for 72 h observed by inverted microscope is shown in Figure 4 and Figure 5. The dose-effect curve of VEGFA is shown in Figure 6, showing that VEGFA significantly promoted cell proliferation of ECV304 cells. The ED50 for this effect is typically 5.58 to 9.98 ng/ml.

Concentration: Prior to lyophilization: 200 µg/ml

Note: THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Abbexa LTD, Cambridge, UK · Phone: +44 (0) 1223 755950 · Fax: +44 (0) 1223 755951
Abbexa LLC, Houston, TX USA · Phone: +1 832 327 7413
Abbexa BV, Leiden, NL
Website: www.abbexa.com · Email: info@abbexa.com